Torrance, California – September 24, 2024 – Proteas Health (www.proteashealth.com) is thrilled to announce its partnership as the preferred proteomic CRO for Perha Pharmaceuticals (www.perha-pharma.com). Leveraging Proteas Health’s industry-leading proteomics platform, this collaboration supports the Phase 1 clinical trial of Leucettinib-21, a groundbreaking drug candidate designed to treat cognitive disorders, including those linked to Down syndrome and Alzheimer’s disease.
Leucettinib-21, a potent DYRK1A kinase inhibitor, was selected from over 1,200 analogs derived from the marine sponge compound Leucettamine B. Now in Phase 1 trials, the drug has been approved by the French National Agency for the Safety of Medicine and Health Products (ANSM). This initiative is financially backed by the European Innovation Council Accelerator program and the Jérôme Lejeune Foundation, both committed to advancing transformative treatments for cognitive disorders.
Proteas Health’s Role
Proteas Health, under the leadership of CEO Dr. Raj Nihalani, COO Arie Shen, and co-founders Dr. Spiros D. Garbis and Dr. Antigoni Manousopoulou who developed its cutting-edge proteomics platform, was recognized as the most advanced in the field of drug discovery. This platform provides high-precision analysis of proteomic and phosphoproteomic biomarkers, delivering insights that surpass the capabilities of any other current proteomic technology.
“Our proprietary platform’s unique ability to detect proteins and phosphoproteins that other technologies struggle is truly transformative for Phase 1 clinical trials like this,” said Dr. Raj Nihalani, CEO of Proteas Health. “We are confident that our partnership with Perha Pharmaceuticals will accelerate the development of innovative therapies for cognitive disorders. By leveraging our state-of-the-art proteomics capabilities, we offer unparalleled products and services that will reshape the future of predicting, detecting and treating heart disease, obesity, cancer, and other unmet clinical needs.”
Dr. Spiros D. Garbis, PhD, a pioneering expert in proteomics with over 30-years of industrial, government and academic experience in the field, added: “This partnership aligns perfectly with our mission to drive precision medicine by providing critical insights into disease mechanisms and therapeutic responses across multiple therapeutic areas.”
About Perha Pharmaceuticals
Perha Pharmaceuticals, founded by Dr. Laurent Meijer in Roscoff, Brittany, France, focuses on developing inhibitors of disease-relevant protein kinases. Their research targets cognitive disorders, cancer, and other diseases, with a commitment to translating marine-based resources into clinical-stage therapies.
Dr. Laurent Meijer, a globally leading authority in Medicinal Chemistry and Drug Discovery, added: “The Proteas Health platform is non-invasive and has been optimized to preserve rare and fragile proteins, setting a new benchmark in proteomics for investigating complex diseases and evaluating new drug candidates’ efficacy.”
As the preferred proteomics CRO for Perha Pharmaceuticals, Proteas Health is proud to help bring Leucettinib-21 step closer to commercialization, offering hope to patients suffering from cognitive disorders related to Down syndrome and Alzheimer’s disease.
For more information, please contact:
Arie Shen
Proteas Health
Arie@proteashealth.com